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Abstract
Background: Elevation of C-reactive protein (CRP) is associated with acute coronary events.
CRP is related to cardiovascular risk factors and adipokines. The aim of the study was to reveal
the factors associated with elevated CRP levels in patients with ST-segment elevation acute
myocardial infarction (STEMI). As there are sex-related differences in plasma levels of CRP
and adipokines, our study was designed for males.
Methods: Seventy men admitted within the initial 6 hours of STEMI were categorized into
4 groups according to the quartile of CRP. Clinical data and laboratory measurements were
analyzed.
Results: Anthropometric measurements, glucose at admission, resistin, and leptin were
significantly higher, and adiponectin lower with the increase of CRP quartile. A significant
positive correlation between CRP and body mass index, waist circumference, glucose at admis-
sion, resistin, and leptin and a negative relation of CRP to HDL-cholesterol and adiponectin
were observed. In univariate logistic regression analysis, variables associated with a level of
CRP above the fourth quartile were history of angina, obesity, diabetes, glucose at admission,
resistin, leptin, and adiponectin, and independent predictors were glucose at admission and resistin.
To predict the elevated CRP level the optimal cut-off for glucose at admission was 144 mg/dL (sensitiv-
ity 84%, specificity 86%) and for resistin was 21.5 ng/mL (sensitivity 79%, specificity 71%).
Conclusions: Glucose at admission and resistin are independently associated with elevated
levels of CRP in men during the early stage of STEMI. (Cardiol J 2009; 16: 36–42)
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Introduction
C-reactive protein (CRP) and high-sensitivity
CRP (hs-CRP) are recognized as valuable inflamma-
tory biomarkers, but a growing body of evidence
supports the active role of CRP in the devolvement
of vascular damage. Hyperresponsiveness of the
inflammatory system is observed in patients with
unstable coronary disease, and this state is further
enhanced by CRP [1]. The exact mechanisms that
associate CRP with atherosclerosis and its compli-
cations are not fully understood. It has been sug-
gested that CRP facilitates a proinflammatory and
proatherosclerotic phenotype mostly by the activa-
tion of nuclear factor-kappa B signal transduction
pathway in peripheral blood monocytes and endo-
thelial cells [2, 3].
Chronic elevation of blood CRP and hs-CRP
levels has been observed in individuals with cardio-
vascular risk factors such as diabetes, smoking,
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obesity, hypertension, and dyslipidemia. White adi-
pose tissue is recognized as an active endocrine and
paracrine organ which has an impact on energy ba-
lance, glucose and lipid metabolism and is responsi-
ble for a low-grade, subclinical inflammatory state
[4–6]. There are, however, significant sex-related
differences in the location of the adipose tissue, the
number of fat cells and fat cell size, plasma levels
of CRP and adipokines [7].
The association between adipokines and mar-
kers of inflammation have been previously demon-
strated in cohorts of healthy subjects, patients with
diabetes, and patients with coronary artery disease
[5, 8–12]. In the course of acute myocardial infarc-
tion, hyperglycemia on admission has been reve-
aled as a new factor associated with increased
levels of inflammatory markers [13].
CRP levels within 6 hours of the onset of myo-
cardial infarction reflect the baseline levels of blo-
od CRP and indicate the vulnerability of coronary
lesions that follow the plaque rupture, not being
affected by the myocardial necrosis [14, 15]. More-
over, in acute coronary syndromes, CRP is predic-
tive of adverse cardiovascular outcome [16].
The associates of the elevated CRP level in
male patients with acute myocardial infarction
that might have an impact on the instability of the
culprit coronary lesion have not been fully eluci-
dated.
The aim of the study was to reveal the factors
most significantly associated with blood levels of
CRP in male patients at the early stage of ST-seg-
ment elevation acute myocardial infarction (STEMI).
Methods
The detailed information concerning methods
is presented in our previously published study in
which we focused on the relation between obesity
and low grade inflammation in acute myocardial in-
farction [17].
Study population
Seventy male patients successfully treated
with primary percutaneous coronary intervention
(TIMI flow grade 3, residual stenosis < 30%) within
the initial 6 hours of STEMI, aged £ 65 years, were
categorized into 4 groups according to the quartile
of CRP: group I < 2.04 mg/dL, group II ≥ 2.04 mg/dL
and < 3.60 mg/dL, group III ≥ 3.60 mg/dL and
< 7.00 mg/dL, group IV ≥ 7.00 mg/dL. Clinical data,
body mass index (BMI), waist circumference, CRP,
lipid profile, and adipokines — leptin, adiponectin,
and resistin were analyzed.
Acute and chronic inflammation or infection,
autoimmune diseases, liver, and thyroid and kidney
diseases were exclusion criteria. Additional exclu-
sion criteria were applied due to the unreported (in
this study) requirements for the acquisition of echo-
cardiographic parameters: atrial fibrillation, atrio-
-ventricular or bundle branch block, temporary or
permanent stimulation, significant valvular heart
disease, and technical problems with echocardiogra-
phic data acquisition. Only those patients who gave
informed consent entered the study.
Anthropometric measurements,
clinical definitions, and treatment
Diagnosis of STEMI was based on clinical
symptoms, electrocardiographic signs, and eleva-
tion of myocardial necrotic markers. All patients
received aspirin, and those who underwent stenting
were concomitantly treated with an additional anti-
platelet agent. Heparin was infused during the pro-
cedure. Glycoprotein IIb/IIIa inhibitor was admini-
stered in a similar proportion of patients from both
groups. The following pharmacological treatment
with aspirin, clopidogrel, statins, beta-blockers,
inhibitors of angiotensin II, nitrates, and diuretics was
similar in both groups. BMI was calculated as body
weight divided by height squared (kg/m2). Weight
and height were measured while the subjects were
fasting. Waist circumference was measured at the
widest diameter between the xiphoid process of the
sternum and the iliac crest. Diabetes, hypertension,
and dyslipidemia were defined when diagnosed pre-
viously or in-hospital.
The study was approved by the Internal Ethics
Committee of the Medical University of Łódź, and
each patient gave informed consent.
Laboratory measurements
and echocardiography
CRP and glucose were determined at admis-
sion, as well as fasting lipid profile, resistin, leptin,
and adiponectin. Plasma triglycerides (TG) and to-
tal cholesterol (TCH) were measured by enzymatic
analytical chemistry. HDL-cholesterol (HDL-CH)
was precipitated using dextran-sulphate and measured
enzymatically. The LDL-cholesterol (LDL-CH) was
calculated using the Friedewald equation: LDL-CH =
= TCH – (TG/5) – HDL-CH. CRP concentrations
were measured with an immunoturbidimetric assay.
Fasting blood samples for measurements of adipo-
kines were taken the day after admission and pla-
sma was frozen at –70° until analysis with the qu-
antitative sandwich enzyme immunoassay techni-
que (ELISA) obtained from R&D Systems Inc.
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Echocardiographic study was performed on the
2–3rd day after admission. Left ventricular ejection
fraction (LVEF) was assessed at 4- and 2-chamber
apical views with biplane Simpson’s formula to eva-
luate left ventricular systolic function.
Statistical analysis
Continuous data were expressed as mean ±
± standard derivation (SD). Variables were log-
-transformed before statistical analysis, if necessa-
ry. Differences between groups were compared
using one-way analysis of variance (ANOVA), Le-
ast Significant Difference method (LSD) was used
for the post-hoc test. Categorical variables were
presented as number and percentage of patients,
and comparisons between the analyzed groups were
performed with the c2 test or Fisher’s exact test,
as appropriate. The association between CRP level
and analyzed parameters (clinical, anthropometric
and biochemical) was examined using Pearson’s or
Spearman’s correlation coefficient, as appropriate.
The independent predictors of elevated levels of
CRP were identified using multivariate logistic re-
gression analysis including variables that were si-
gnificantly associated with CRP in univariate ana-
lysis. The variables included in the univariate logi-
stic regression analysis were: age, history of angina,
multivessel disease, smoking, obesity, hyperten-
sion, diabetes, glucose at admission, dyslipidemia,
resistin, leptin, and adiponectin. The results were
expressed as odds ratio (OR) and 95% confidence
intervals (CI). Receiver operating characteristic
(ROC) curve analysis was used to determine the
cut-off values for hyperglycemia and resistin, which
were identified as independent predictors of eleva-
ted CRP level in multivariate logistic regression
analysis. Results were expressed in terms of the
area under the curve (AUC) and 95% CI for this
area. Optimal cut-off of the CRP level above the
fourth quartile was chosen when the sensitivity and
specificity were maximized. A p value less than 0.05
was considered to be statistically significant. Stati-
stical analysis was performed using Statistica so-
ftware (version 6.0, Statsoft, Tulsa, OK, USA) and
MedCalc statistical software (version 7.2.1.0 for
Windows; Mariakerke, Belgium).
Results
The clinical characteristics and biochemical
parameters of the study group are presented in
Table 1. The incidence of obesity, dyslipidemia,
diabetes, and history of angina increased in the
upper quartiles of CRP. There was no significant
difference in mean age, smoking, hypertension,
time since the onset of symptoms to admission, lo-
calization of myocardial infarction, multivessel di-
sease, and LVEF between the study groups. The
assessed anthropometric measurements (BMI and
waist circumference), as well as glucose at admis-
sion, resistin, and leptin, were significantly higher
and adiponectin was significantly lower with the in-
crease of CRP quartile.
A positive correlation between CRP and BMI
(r = 0.44, p < 0.001), waist circumference (r = 0.41,
p < 0.0001), glucose at admission (r = 0.29, p < 0.05),
resistin (r = 0.41, p < 0.0001), and leptin (r = 0.43,
p < 0.001) and a negative correlation between CRP
and HDL-CH (r = –0.23, p < 0.05) and between
CRP and adiponectin (r = –0.50, p < 0.0001) was
observed (Table 2).
As revealed by univariate logistic regression
analysis, predictors of elevated CRP were: history
of angina, obesity, diabetes, glucose at admission,
resistin, leptin, and adiponectin. In the multivaria-
te model independent variables associated with
levels of CRP above the fourth quartile were: glu-
cose at admission (OR = 1.07; 95% CI 1.03–1.11;
p = 0.0003) and resistin (OR = 1.52; 95% CI 1.09–
–2.11; p = 0.0122) (Table 3).
Figure 1 shows the area under the ROC curves
for glucose at admission and resistin, as predictors
of elevated CRP level (AUC 0.92, 95% CI 0.83–0.97;
AUC 0.76, 95% CI 0.65–0.86, respectively). The opti-
mal cut-off for glucose at admission was 144 mg/dL
(sensitivity 84% and specificity 86%) (Fig. 1A) and
21.5 ng/mL for resistin (sensitivity 79% and speci-
ficity 71%) (Fig. 1B).
Discussion
The principal finding of our study was the de-
monstration that at the early stage of STEMI, ad-
mission hyperglycemia and resistin are independen-
tly related to the elevated CRP level.
Acute hyperglycemia is a phenomenon com-
monly seen in patients with acute myocardial infarc-
tion even when they have never been previously
diagnosed with diabetes [18]. In these patients ad-
mission hyperglycemia was related to CRP and other
markers of the inflammatory immune process [13],
and it was recognized as a factor negatively affec-
ting outcome [19]. Close interrelation between glu-
cose metabolism and inflammation has been shown
in several studies. Chronic inflammation is involved
in an early process in the pathogenesis of diabetes
[20], and, conversely, high levels of blood glucose,
even in levels within the normal range, promote
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inflammation in the vascular cells [21–23]. A possi-
ble pro-inflammatory mechanism of action of hypo-
glycemia is the induction of cytokine secretion by
monocytes and adipocytes [24]. Interesting obse-
rvations from the study of Schillinger et al. [25]
show that inflammation is expressed by elevated hs-
CRP and hyperglycemia is expressed by elevated
glycosylated hemoglobin A1c, which jointly contri-
bute to the cardiovascular risk of patients with ad-
vanced atherosclerosis. The present study confirms
the association between diabetes and inflammation
although their independent relation was not confir-
med. Aggarwal et al. [26], in a study group inclu-
ding more than 80% of patients with acute corona-
ry syndrome, revealed that concentrations of CRP
in patients with diabetes were more than twice as
high as in the rest of the study group, and diabetes
was an independent predictor of elevated CRP con-
centrations.
Although the potential role of resistin as an
independent cardiovascular risk factor has not been
confirmed [27, 28], it has been shown that this
molecule may induce endothelial dysfunction, and
upregulate adhesion molecules and chemokines [29].
In contrast to rodents, in which resistin is derived
almost exclusively from fat tissue, in humans peri-
pheral blood mononuclear cells seem to be a major
source of this molecule [30]. Our study, in agre-
ement with recent data, showed that resistin cor-
relates with inflammatory markers [9, 10] and sug-
gest that resistin is involved in the generalized in-
flammatory process.
We have shown that leptin and adiponectin are
other adipokines which significantly reveal blood
levels of CRP, but they are not independent pre-
dictors of elevated CRP level. In previously publi-
shed reports CRP was associated with leptin in
healthy subjects [11], but this relation was not con-
firmed by Yan et al. [31] in patients with acute myo-
cardial infarction and coronary atherosclerosis.
Adiponectin, which is downregulated in obesity, is
Table 2. Correlation between C-reactive protein
and analyzed parameters.
C-reactive protein
r p
Age (years) 0.16 NS
Body mass index 0.44 < 0.001
Waist circumference 0.41 < 0.0001
Glucose at admission 0.29 < 0.05
Total cholesterol 0.07 NS
HDL-cholesterol –0.23 < 0.05
LDL-cholesterol 0.14 NS
Triglycerides 0.22 NS
Resistin 0.41 < 0.0001
Leptin 0.43 < 0.001
Adiponectin –0.50 < 0.0001
Ejection fraction –0.14 NS
Table 3. Univariate and final model of multivariate logistic regression analysis for the fourth quartile of
blood C-reactive protein level.
Odds ratio –95% confidence interval +95% confidence interval p
Univariate logistic regression analysis
Age (years) 1.0417 0.9601 1.1303 0.3263
History of angina 4.1143 1.3561 12.4823 0.0125
Multivessel disease 2.5218 0.8591 7.3979 0.0919
Smoking 2.0455 0.5898 7.0932 0.2593
Obesity 4.9432 1.4386 16.9853 0.0112
Hypertension 1.6484 0.5588 4.8627 0.3652
Diabetes mellitus 3.3131 1.0367 10.5886 0.0433
Glucose at admission 1.0632 1.0321 1.0952 0.0001
Dyslipidemia 1.6410 0.4077 6.6055 0.4857
Resistin 1.0852 1.0310 1.1422 0.0018
Adiponectin 0.8278 0.6952 0.9856 0.0338
Leptin 1.0293 1.0041 1.0551 0.0223
The final model of multivariate logistic regression analysis
Glucose at admission 1.0728 1.0328 1.1143 0.0003
Resistin 1.5219 1.0961 2.1139 0.0122
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an adipokine which is considered to be a protective
cardiovascular factor [32–34]. Several published
reports have demonstrated that there is an inverse
relationship between plasma adiponectin levels and
CRP [12, 35], and this observation was confirmed
in our group of patients. The association of adipo-
kines and measures of obesity (BMI and waist cir-
cumference as shown in the present study) supports
the idea that excess body fat results in enhanced
systemic inflammation [6, 36].
In the present study, a higher incidence of dia-
betes, dyslipidemia, and obesity and the trend of
a higher incidence of smoking in the upper quarti-
les of CRP were observed. Values of the measures
of obesity were significantly higher and blood levels
of HDL-CH lower in the first quartile of CRP than
in the fourth quartile. These results show that clu-
stering of risk factors, mostly in a configuration
known as metabolic syndrome, is another important
low-grade inflammatory state associated with athe-
rosclerosis and its clinical consequences [35, 36].
Limitations of the study
Our study was designed for males, so the results
can not be generalized for the female population.
Unfortunately we did not measure glycosyla-
ted hemoglobin A1c, which is an indicator of long-
-term glycemic control and is related to systemic
low-grade inflammation. Such information could
give further insight into the impact of glucose
metabolism on the pro-inflammatory action in acute
coronary syndrome.
More precise history of smoking, including the
number of cigarettes smoked per day and period of
active smoking might have shown the previously
revealed [37] significant association between this
factor and CRP levels.
Conclusions
Glucose at admission and resistin are indepen-
dently associated with elevated blood levels of CRP
in patients at the early stage of ST-segment eleva-
tion acute myocardial infarction.
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